



Journey of local anaesthesia from past to recent advances: A review literature

Anurag Yadav¹, Ramakant Dandriyal², Niranjana Prasad Indra B¹, Himanshu Pratap Singh³, Sumit Bhatt⁴

¹ Professor, Department of Oral and Maxillofacial Surgery, Institute of Dental Sciences, Bareilly, Uttar Pradesh, India

² HOD and Professor Department of Oral and Maxillofacial Surgery Institute of Dental Sciences, Bareilly, Uttar Pradesh, India

³ Associate Professor, Department of Oral and Maxillofacial Surgery Institute of Dental Sciences, Bareilly, Uttar Pradesh, India

⁴ Department of Oral and Maxillofacial Surgery, Institute of Dental Sciences, Bareilly, Uttar Pradesh, India

DOI: <https://doi.org/10.33545/26648849.2022.v4.i1a.24>

Abstract

Without a question, the most important part of patient care in dentistry is local pain management. The advancements in local anaesthetic equipment, agents, and techniques are perhaps the most significant achievements in dentistry science, allowing the profession to make major therapeutic advances that would not have been feasible otherwise. The capacity to administer safe and effective local anaesthetic is essential in clinical oral surgery. Like any regional anesthetic technique, the use and effectiveness depends on patient considerations, the extent and duration of the procedure, choice of drug and technique, and the skill and experience of the practitioner. Every clinician should be aware of his or her skill limitations, and the limitations of the contemplated technique and agent. The administration of local anesthetics is often complicated by the existence of multifactorial psychological considerations associated with the delivery of dental care. It is imperative for health care professionals to understand and appreciate these issues to properly implement perioperative behavioral or pharmacologic management strategies to reduce fear and anxiety to acceptable levels.

Keywords: local anaesthesia, recent advances, literature

Introduction

Carl Koller, an Austrian ophthalmologist, demonstrated the effect of cocaine as a local anesthetic for eye surgery in 1884. He instilled drops of cocaine onto the surface of the eye, providing topical anesthesia. For the first time, a patient was able to undergo a surgical procedure awake and without pain. Later the same year, in Baltimore, Maryland, a surgeon, William Halstead, administered an injection of cocaine (with epinephrine) via inferior alveolar nerve block for the removal of a neuroma. Cocaine, considered a “wonder drug,” allowed dental and medical patients to undergo painful surgical procedures painlessly while still conscious. In late November 1884, William S. Halsted and Richard J. Hall first achieved neuroregional anaesthesia in the mandible by injecting a solution of cocaine in the vicinity of the mandibular foramen. Since that revolutionary injection, dentists have possessed the remarkable ability to deliver invasive dental treatment in a pain-free manner and relieve suffering of the patients.

In today's practice an array of options are available for anesthetic agents and delivery equipments to manage pain. Developments in anaesthesia have come a long way since first discovered properties of cocaine to computer controlled anaesthesia with newer agents today. It is possible to perform a dental procedure completely imperceptible to pain if one understands the origin of pain and chooses appropriate agent and technique to alleviate pain. Local anesthesia forms the backbone of pain control techniques in dentistry, and local anesthetics are the safest and most effective drugs in medicine for the prevention and management of pain. Nonetheless, the administration of these drugs is the most frightening and uncomfortable part of the dental appointment for most patients. The needle is the most fear inducing part of the armamentarium for the delivery of LAs. Over the years, many futile attempts have been made to provide clinically adequate pain control without the need for injection of drugs.

Recent advances in equipments resulted in the use of computer-controlled anaesthesia, electronic dental anaesthesia, pressure syringes, vibrajets, accupal, jet injections. Advances in anesthetic techniques that provide alternatives to conventional methods include lingual infiltration, periodontal ligament injections, intraosseous anesthesia, computer-controlled injections, needleless injections, and electronic dental anesthesia. Additionally, new injection techniques that provide reliable anesthesia have also been introduced, and depending on the technique used and area of anesthesia necessary, they do not result in undesired extraoral soft tissue anesthesia i.e anterior middle superior alveolar block, palatal approach anterior superior alveolar nerve block and a new app

-roach to inferior alveolar nerve block. Newer anaesthetic agents are oraverse, articaine hydrochloride, sodium bicarbonate with local anaesthesia, lidocaine and prilocaine periodontal gel.

Advances in Anaesthetic Equipment

Computer Controlled Anesthesia

The dental syringe is a drug delivery device requiring that the operator simultaneously attempt to control the variables of drug infusion and the movement of a penetrating needle. The operator's inability to precisely control both of these activities during an injection can compromise an injection technique. In addition the traditional syringe is handled with a palm-thumb grasp, which is not designed for ideal ergonomics or needle control during the injection.

Milestone Scientific (Piscataway, NJ, USA) introduced the first C-CLAD system in the United States in 1997^[4]. Originally known as the Wand, subsequent versions were sequentially renamed the Wand Plus and then CompuDent, the current designation in 2001 is the Comfort Control Syringe.



Fig 1

The wand (Milestone Scientific, New Jersey) was designed to improve on the ergonomics and precision of the dental syringe. The CCLAD technology had helped to redefine our perception and, even more important, the perception of our patients, as to how local anesthesia can and could be achieved^[5]. The operator focuses attention on needle insertion and positioning, allowing the motor in the device to administer the drug at a pre-programmed rate of flow.

The C-CLAD devices provide clinicians with the ability to precisely control the rate of delivery of the local anesthetic solution^[6]. In addition, it also introduced the concept of using a disposable handpiece weighing less than 10gm, allowing the clinician to hold it in a pen like fashion, greatly increasing tactile control and improving dexterity during injection^[4]. The wand system administers local anaesthesia at two specific rates of delivery. The slow rate is 0.5ml/min and the fast rate is 1.8ml/min. An aspiration cycle can be activated at any time by simply pressing the pressure on the foot-rheostat starting a 4.5 second aspiration cycle. The wand permits both a precise rate of flow and a controlled pressure to be maintained irrespective of the type of tissue into which the local anaesthetic is being deposited. Therefore even tissues with low elasticity receive a constant pressure and rate of flow, resulting in a more favourable (comfortable, less tissue damage) outcome.

Comfort Control Syringe: The Comfort Control Syringe differs from the Milestone products in that there is no foot pedal. It has two main components: a base unit and a syringe. Several functions of the unit, most importantly injection and aspiration can be controlled directly from the syringe, possibly making its use easier to master for practitioners accustomed to the traditional manual syringe.

Comfort control syringe (CCS) system was introduced several years after The Wand. The CCS has a two-stage delivery system; the injection begins at an extremely slow rate to prevent the pain associated with quick delivery. After 10 seconds, the CCS automatically increases speed to the pre-programmed injection rate for the technique selected. It has five different basic injection rate settings designed for specific injections: block, infiltration, PDL, IO, and palatal injection.



Fig 2

CompuFlo technology

In 2001, Hochman and colleagues advanced the science and understanding of subcutaneous injection fluid dynamics by identifying a predictable method for measuring the precise value of fluid exit pressure in situ (at the tip of the needle) during drug administration [7]. This approach to fluid injection dynamics is called dynamic pressure sensing technology, which was developed for the delivery and aspiration of medicaments [8]. In 2007, CompuFlo technology was applied in dentistry to address an important challenge: performing more predictable single tooth anesthesia (e.g., the PDL injection). With the decreasing trend of generalised dental caries and increasing trend towards site specific treatment of an individual tooth, the use of nerve block anesthesia has become less necessary [9].

Electronic Dental Anesthesia

Electronic dental anesthesia/transcutaneous electric nerve stimulation (TENS) is a technique that provides us a promising way to produce dental anesthesia by using a mild amount of electric current and is based on the much-established Gateway Theory of pain control given by Malzack and Wall in 1965. According to Allgood, "TENS is the direct stimulation of the nerves by short-duration, small amplitude electric pulses." TENS units are grouped into three categories. High-frequency (25-150 Hz) is the mode used most frequently to manage chronic TMJ pain, acute postoperative pain, and to provide EDA. Low frequency (2-10 Hz) is used when high-frequency TENS becomes ineffective because of accommodation during treatment of chronic pain. Ultralow-frequency (0.5-2 Hz) is again useful for treating chronic TMJ pain and measuring accurate vertical dimension of rest.



Fig 3

Pressure Syringes

First introduced in 1970, pressure syringes brought a renewed interest in periodontal/intraligamentary injection technique. It has made it possible to achieve consistently reliable pulpal anaesthesia of one isolated tooth. The original pressure devices, Peripress and Ligmajet were modeled after a device that was available in dentistry in 1905 – The Wilcox Jewett Obtunder.



Fig 4

Jet Injections ^[14]

First use of jet injections in dentistry was in 1958 by Margetis and associates. It is based on the principle that liquids forced through very small openings called jets at very high pressure can penetrate intact skin or mucous membrane. The primary use of the jet injector is to obtain topical anaesthesia before the insertion of a needle. Regional nerve blocks or supraperiosteal injections still are necessary for complete anaesthesia.

The syrijet (Mizzy, precision instruments – New Jersey) and Madajet (Mada Medical products), developed in 2003 are the most used jet injectors in dentistry. The Syrijet holds any 1.8ml dental cartridge of local anaesthetic. It is calibrated to deliver 0.05 to 0.2ml of solution at 2000 psi. The Syrijet will provide subtopical anaesthesia to a depth of 1.5cm for painless needle insertion.




Fig 5

Advances in Anaesthetic Techniques

Lingual Infiltration

A relatively new concept, lingual infiltration of the mandible, theoretically and practically has merit but may also pose some disadvantages ^[19]. As with any other technique, patient (anatomical) selection is important. It should be reinforced that, although mandibular infiltration is generally regarded as not reliably successful, certain conditions may establish profound anaesthesia via the combination of facial (buccal) and lingual injection.

Advantages

Thin cortical plate, Lingual foramina
Patient acceptance

Disadvantages

Ballooning of tissue

Periodontal Ligament Injection

The introduction of the intraligamentary injection techniques popularized by the Ligmaject in the 1970s is an actual intraosseous delivery of local anesthesia, provides a supplement to routine submucosal anesthesia [20]. For the route of administration commonly known as the periodontal ligament injection (PDL), it must be understood that the PDL space is simply the anatomical medium to deliver an intraosseous injection. Success rates with the intraligamentary technique are variable, depending on practitioner's experience, volume of solution injected, and the tooth being anesthetized.

Although intraligamentary injections appear to have a slightly lower success rate, their use for diagnostics in referred pain states, with uncontrolled hemophiliacs and as an adjunct following failed mandibular blocks, appears quite valuable. Initially, injection into the PDL tissue occurs by advancement of a 30 or 27 gauge short needle to the point of obtaining significant back pressure on injection, a criterion required for the local anesthesia successfully to penetrate the cribiform plate and circumferentially anesthetize even in an abscessed or "hot" tooth.

The volume of solution required is approximately 0.4–0.9 mL per administration, and recommendations for mandibular molars include a 2-site approach (mesial lingual and distal lingual). The duration will vary from 5 to 25 minutes, depending on volume, clearance, protein binding, and vasoconstrictor concentration [20].

Intra-Osseous Anesthesia

Although IO-induced local anesthesia has been used in clinical dentistry for over a century, the original technique was too invasive for widespread adoption, requiring a gingival flap to be raised to gain access to the buccal cortical bone for perforation with a small round bur. It became even less important with the discovery and marketing of lidocaine in the 1940s. Nevertheless, in 1975 Lilienthal described a technique in which a handpiece-driven root canal reamer was used to perforate the cortical plate. This use of a motor-driven perforator to penetrate the buccal gingiva and bone may be considered the first modern technique of IO anesthesia and the foundation upon which all current methods are based.

The intraosseous (IO) injection involves placement of a local anesthetic directly into the cancellous bone adjacent to the tooth to be anesthetized, and is used primarily in endodontic practice. One of the benefits of the IO injection is the reported immediate onset of anesthesia. The injection is recommended to be given distal to the tooth to be anesthetized. The exception to this rule would be the maxillary and mandibular second molars, for which a mesial site injection would be needed. The perforation site for the IO injection should be equidistant between the teeth and in the attached gingiva to allow for the perforation to be made through a minimal thickness of tissue and cortical bone and to prevent damage to the roots of the teeth. Clinical experience has shown that local anesthetics seem to be significantly less effective in endodontic pain patients who present with signs and symptoms of irreversible pulpitis and/or acute peri radicular inflammation, secondary to either an apical extension of pulpal inflammation or pulpal necrosis and bacterial invasion. Clinical studies have reported that a single inferior alveolar nerve (IAN) block injection of local anesthetic (1.8 mL) is ineffective in 30% to 80% of Patients with irreversible pulpitis [21]

Advances in Anaesthetic Agent

Articaine Hydrochloride

In 1969, articaine hydrochloride, with a chemical code name of Hoe 40 45, was synthesized by H. Rusching *et al.* as the first amide type drug with a lipophilic thiophene ring and additional ester side chain. It was originally known as "carticaine", the generic nomenclature of this local anesthetic was changed in 1984 to Articaine.




Fig 6

It was introduced in Switzerland and Germany in 1976, Canada in 1983, USA in 2000. More recently, use of 4% Articaine with epinephrine 1:1, 00,000 and with epinephrine 1:2, 00,000 was approved in 2006 by the FDA. The amide structure of articaine is, in general, similar to that of other local anesthetics. It is unique, however, among the amide local anesthetics in that it does not contain a benzene ring like the others but instead contains a thiophene ring. The thiophene ring increases its liposolubility, making it more effective in crossing lipid barriers.

It also contains an additional ester group, which enables articaine to undergo biotransformation in the plasma (hydrolysis by plasma esterase) as well as in the liver (by hepatic microsomal enzymes) 2.

Articaine HCl does not possess any relevant systemic side effects or gross toxicity, and can be considered a safe local anesthetic [29]. The safety and efficacy of articaine has been studied, and it has been found to be a well-tolerated, safe, and effective local anesthetic for use in clinical dentistry that will meet the clinical requirements for pain control of most dental procedures in most patients. Its lower systemic toxicity and wide therapeutic range permits the use of articaine in higher concentrations than other amide-type local anesthetics [30].

Articaine reaches its peak blood concentration in about 25 minutes following a single-dose dental injection by the sub mucosal route of a solution containing 1:200,000 epinephrine. It diffuses better through soft tissue and bone than other local anesthetics. The concentration of articaine in the alveolus of a tooth in the upper jaw after extraction was about 100 times higher than that in systemic circulation [31]. Approximately 60% to 80% of articaine HCl is bound to human serum albumin and gamma globulins, and is rapidly metabolized by plasma carboxyesterase to its primary metabolite articainic acid which is secreted by the kidneys as an inactive metabolite. The elimination half-life is 20 minutes. The onset of anesthesia is within 1 to 9 minutes after injection, and complete anesthesia lasts approximately 1 hour for infiltrations and up to approximately [2] hours for nerve block.

Articaine is known to possess enhanced diffusion properties and better anaesthetic efficacy. It has been described as having potency 1.5 times that of lidocaine and 1.9 times that of procaine, fast onset and increased success rate, with dentists reporting that they 'don't miss as often'. Articaine's superiority was mainly founded on the notion that its thiophene ring bestows enhanced performance. This feature has been credited with providing increased lipid solubility and protein binding, two properties theoretically related to increased anaesthetic efficacy. Lipid solubility is an intrinsic quality of local anesthetic potency. This quality is essential for penetration of the anesthetic through the lipid nerve membrane and subsequent diffusion into surrounding tissues.

Sodium Bicarbonate with Local Anaesthesia

Chemically, amide local anaesthetics are weak bases. Commercial local anaesthetic cartridges are purposefully formulated as relatively acidic solutions (compared with the physiologic pH of 7.4) in order to enhance the solubility of the anaesthetic salts and to prolong shelf life. Typically, commercial lidocaine solutions have a pH of about 3.9. The pH of the solution is important because it affects the way anaesthetic works. Like most other injectable local anaesthetics, lidocaine with epinephrine solution contains two forms of the anaesthetic salt.



Fig 7

(i) The uncharged, de-ionized, or "active" free base form, which is lipid soluble; and charged or ionized cationic form, which is not lipid soluble. The de-ionized form more readily penetrates the nerve membrane to enter the nerve axon, where the anaesthetic attaches to receptors on the sodium channels, resulting in a blockade of nerve conduction. This biochemical process makes the relative availability of de-ionized anaesthetic important in creating clinical analgesia. According to the Henderson-Hasselbalch equation, in any sample of local anaesthetic solution the ratio of the de-ionized species of the anaesthetic to the ionized species of the anaesthetic is based on the pH of the sample. At a more acidic pH, the ionized cationic form predominates. For instance, at a pH of 3.9, a typical cartridge of lidocaine with epinephrine contains only 1 molecule of de-ionized anaesthetic for every 10,000 molecules of ionized anaesthetic. On the other hand, closer to physiologic pH, more de-ionized anaesthetic is present. For instance, at the physiologic pH of 7.4 there is one molecule of de-ionized lidocaine in solution for every 4 molecules of ionized lidocaine. At the physiologic pH, then, there is 2,500x more of the active form of the anaesthetic available than at pH 3.9. Normally, the body buffers the local anaesthetic after injection toward physiologic pH, which eventually increases the availability of de-ionized anaesthetic. Over time, as this *In vivo* buffering process continues, more and more of the de-ionized or active form of the anaesthetic is available. This ultimately leads to nerve blockade. After injection, tissue buffering raises the pH and a percentage of the drug dissociates to become free bases, the amount depending upon the 'dissociation

constant' of the individual anaesthetic. Being lipid soluble, the free base is able to penetrate both the nerve coverings and the lipid cell membrane to reach the interior of the axon where a portion re-ionizes. The re-ionized portion enters the sodium channels and plugs these channels so that sodium ions cannot enter the cell. As a result, action potentials are neither generated nor propagated and conduction blockade occurs.

Injection Pain and pH

It has been shown in adult volunteers that buffering lidocaine with sodium bicarbonate just prior to skin infiltration can significantly reduce the painful burning sensation without compromising anaesthetic efficacy. There are two possible mechanisms by which increasing the pH of lidocaine could decrease the pain associated with its injection. Increasing the pH increases the amount of lidocaine in uncharged form, which could either be less irritating to the tissues than the charged form or, alternatively, be capable of entering the nerve sheath much more rapidly than the charged form, thereby blocking pain transmission almost instantaneously.

The pain caused by infiltration of anaesthetic solutions into the skin is largely attributed to their acidity. Solutions with lower pH cause increased pain by two different mechanisms. The acidity of the solution causes a burning sensation when infiltrated into more neutral tissues due to tissue irritation. In addition, at a lower pH less of the anaesthetic is in its active, freely diffusible form, leading to a prolonged time until onset of anaesthesia. In a more neutral, buffered solution the area is anesthetized more quickly and further infiltration is less painful.

The Role of CO₂ in Creating More Comfortable Injections

When sodium bicarbonate solution is mixed with a local anaesthetic like lidocaine with epinephrine, the interaction of the sodium bicarbonate (NaHCO₃) with the hydrochloric acid (HCL) in the local anaesthetic will, among other things, create water (H₂O) and carbon dioxide (CO₂). The CO₂ will begin to diffuse out of solution; the diffusion beginning immediately and occurring even after the solution has been injected. Catchlove^[35] reported that CO₂ in combination with lidocaine potentiates the action of lidocaine by (i) a direct depressant effect of CO₂ on the axon; (ii) concentrating the local anaesthetic inside the nerve trunk through ion trapping; and (iii) changing the charge of the local anaesthetic inside the nerve axon. Condouris and Shakalis^[36] demonstrated that CO₂ possesses an independent anesthetic effect and caused a sevenfold potentiation in anesthetic action. Research has proven reduced injection pain to the rapidity with which pain signals are blocked when using buffered anaesthetic. It also points to a mechanism by which *In vitro* buffering with sodium bicarbonate reduces injection pain. Because of the potential loss of CO₂ from the solution over time, it is recommended that buffering should take place immediately before giving the injection, versus allowing a delay between buffering the anaesthetic and delivery^[34].

Oraqix (Lidocaine & Prilocaine Periodontal Gel 2.5%/2.5%)

Oraqix is a topical anesthetic agent introduced in 2004, and is designed primarily for use by dental hygienists. The FDA approved Oraqix for periodontal applications. It is a needle-free subgingival anesthetic for use in adults requiring localized anesthesia in periodontal pockets during scaling and/or root-planing procedures [2]. Oraqix is an oil at room temperature, so it can be easily applied into periodontal pockets requiring root planing and scaling. Once applied it solidifies at body temperature into an elastic gel, enabling it to remain in place while the anesthetics take effect. It is applied on the gingival margin around the selected tooth using a blunt-tipped Oraqix applicator. Scaling and root planing may begin 30 seconds after the application, and the anesthetic effect has a duration of approximately 20 minutes.

Oraqix offers minimal risk for an allergic reaction, and it may be reapplied to a maximum of 5 treatment cartridges if longer duration of the anesthetic effect is required. Overdose reactions are similar to overdoses from injectable amides.

Conclusion

Local anesthesia has been the cornerstone of modern day pain-free dental practice. However, the practitioners' limitations in updating about newer drug formulations available and newer techniques to administer the drugs has, still not made the goal of pain-free dentistry a reality. The availability and cost factors are not excuses not to adapt newer proven methods, when the benefits outweigh the shortcomings. There is a need in the current evidence-based era of dental practice for us to constantly update, evaluate and incorporate newer drugs and techniques into daily practice to provide our patients the best of care at all times.

References

1. Giovannitti *et al.* Pharmacology of Local Anesthetics Used in Oral Surgery Oral Maxillofacial Surgery Clinics North America, 2013;25:453-465.
2. Ogle, Mahjoubi. Dental Clinics North America, 2011;55:481-499.
3. Available at: <http://www.drugs.com/oraverse.html>. Accessed August, 2010.
4. Hochman MN, Chiarello D, Hochman CD *et al*: Computerized local anesthetic delivery vs. traditional syringe technique: subjective response, N Y Dent J, 1997;63:24-29.
5. Clinical Research Associates: Local anesthesia, automated Freidman MJ, delivery, Clinical Res Associates Newsltr, 1999;22:1-2.
6. Freidman MJ, Hochman MN. 21st century computerized injection for local pain control, CompendContinEdu Dent, 1997;18:995-1003.

7. Hochman MN, Inventor: Pressure/Force computer controlled drug delivery system and the like, US. Patent,2001:7:618,409.
8. Hochman MN. Inventor: Computer controlled drug delivery system with dynamic pressure sensing, U.S. Patent,2006:7:618:409.
9. Hochman MN. Single tooth anesthesia: Pressure sensing technology provides innovative advancement in the field of dental local anesthesia, Compendium,2007:28:186-193.
10. Melzack R, Wall PD. Pain mechanism: A new theory. *Science* 1965;150:971-8.
11. Allgood JP. Transcutaneous electrical neural stimulation (TENS) in dental practice. *CompendContinEduc Dent*,1986:7:640-44.
12. Adams E. Naloxone reversal of analgesia produced by brain stimulation in the human. *Pain*,1976:2:161-66.
13. Abram SE, Reynolds AC, Cusick JF. Failure of naloxone to reverse analgesia from transcutaneous electrical stimulation in patients with chronic pain. *AnesthAnalg*,1981:60:81-84.
14. Dabarakis N, Alexander V, Tsirlis A *et al*. Needle-less local anesthesia: clinical evaluation of the effectiveness of the jet anesthesia Injex in local anesthesia indentistry. *Quintessence Int*,2007:38(10):572-6.
15. Blair J. Vibraject from ITL dental. *Dent Econ*,2002:92:90.
16. Available at: <http://www.Dentalvibe.com>. Accessed August, 2010.
17. Available at: <http://www.accupal.com>. Accessed August, 2010.
18. Dower JS, Barniv ZM. Periodontal ligament injection: review and recommended technique. *Gen Dent*,2004:52:537-542.
19. Hawkins JM, Moore PA. *Dent Clin N Am*,2002:46:719-732.
20. Kaufmen E, Dworkin SF, LeResche L, Truelove EL, Sommers E. Intraligamentary anesthesia: a double-blind comparative study. *J Am Dent Assoc*,1984:108:175-8.
21. Nusstein J, Reader A, Nist R, *et al*. Anesthetic efficacy of the supplemental intraosseous injection of 2% lidocaine with 1:100,000 epinephrine in irreversible pulpitis. *J Endod*,1998:24:487-91.
22. Khan A, Ren K, Hargreaves K. Neurochemical factors in injury and inflammation of orofacial tissues. In: Sessle B, Lavigne G, Lund J, *et al*, editors. *Orofacial pain: basic sciences to clinical management*. Chicago: Quintessence Publications,2001:1:45-52.
23. Smith GN, Smith SA. Intrapulpal injection: distribution of an injected solution. *J Endod*,1983:9:167-70.
24. Dunbar D, Reader A, Nist R *et al*. Anesthetic efficacy of the intraosseous injection after an inferior alveolar nerve block. *J Endod*,1996;22:481-6.
25. Replogle K, Reader A, Nist R *et al*. Anesthetic efficacy of the intraosseous injection of 2 percent lidocaine (1:100,000 epinephrine) and 3 percent mepivacaine in mandibular first molars. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*,1997;83(1):30-7.
26. Freidman MJ, Hochman MN. The AMSA injection: a new concept for local anesthesia of maxillary anterior teeth using a computer controlled injection system, *Quintessence Int*,1998:29:297-303.
27. Freidman MJ, Hochman MN. P-ASA block injection: a new palatal technique to anaesthetize maxillary anterior teeth, *J Esthet Dent*,1999:11:63-71.
28. Paltil DG *et al*: Anesthetic technique for inferior alveolar nerve block: a new approach, *J. Appl. Oral Sci*,2011:19(1).
29. Leuschner J, Leblanc D. Studies on the toxicological profile of the local anaesthetic articaine. *Arzneimittelforschung*,1999;49:126-32.
30. Oertel R, Ebert U, Rahn R, *et al*: The effect of age on pharmacokinetics of the local anesthetic drug articaine. *Clin Pharmacokinet*,1997;33:417-25.
31. Vree TB, Gielen MJ. Clinical pharmacology and the use of articaine for local and regional anaesthesia. *Best Pract Res Clin Anaesthesiol*,2005:19:293-308.
32. Tuncel M, Ram VC. Hypertensive emergencies: etiology and management, *Am J Cardiovasc Drugs*,2003;3:21-31.
33. Phentolamine MD. Consult, St Louis, CV Mosby, accessed June 26,2011. 34. Stanley F. Malamed Handbook of local anesthesia 6th edition, 2010.